On April 15, 2025, Fortis Gurugram launched the Fortis Institute of Genomic Medicine, a pioneering centre dedicated to harnessing the power of genomic science to transform patient care. Backed by Fortis’ advanced clinical ecosystem and Agilus Diagnostics’ extensive national footprint, the institute brings together a multi-disciplinary team of medical experts from Molecular Hematology, Oncology, Neurology, Pediatrics, Pathology and Genomic scientists along with bioinformaticians and AI (artificial intelligence) engineers.
Genomics is transforming the future of modern medicine and treatment modalities across specialties – Oncology, Cardiology, Neurology. Onco-genomics will help clinicians decode the genetic drivers of cancer, enabling targeted therapies that are more effective and less toxic than traditional one-size-fits-all treatments. Cardio-genomics will empower the early detection of inherited cardiac conditions, crucial for families with a history of sudden cardiac arrest, unexplained heart failure, or congenital heart disease. Meanwhile, Neuro-genomics will offer new hope for patients with complex neurological disorders, using gene-based insights to improve diagnosis and personalize interventions for conditions like epilepsy, Parkinson’s and rare neurodevelopmental syndromes. The power of Genomics has already delivered life-changing outcomes: a leukemia patient, initially headed for a transplant, received a new course of treatment following a precise genetic diagnosis; a woman with a silent hereditary cancer risk underwent genomic screening, leading to early detection and preventive care for three family members; and a lung cancer patient with a previously undetected MET-ST7 fusion (a genetic alteration)—identified solely through Fortis’ Next-Generation Sequencing (NGS)—is now thriving on targeted therapy.
In the near future, Fortis will also launch a Genomics-informed health registry, setting a new benchmark in precision medicine along with India’s first AI-powered genomic reporting platform designed specifically for Indian clinicians as per international recommendations by ACMG (American College of Medical Genetics and Genomics), AMP (Association for Molecular Pathology), and ASCO (American Society of Clinical Oncology), which will be compliant, clinically relevant, and intuitively designed for seamless integration into medical practice.
Senior clinicians and leaders present on the occasion included Dr Rahul Bhargava, Principal Director and Chief, Bone Marrow Transplant, FMRI, Gurugram; Dr Vinayak Agarwal, Senior Director & Head, Non-Invasive Cardiology, FMRI, Gurugram; Dr Praveen Gupta, Principal Director & Chief of Neurology, FMRI, Gurugram; Dr Nitesh Rohatgi, Senior Director, Medical Oncology, FMRI, Gurugram; Dr Ankur Bahl, Senior Director, Medical Oncology, FMRI, Gurugram; Dr Shrinidhi Nathany, Consultant, Molecular Haematology and Oncology, FMRI, Gurugram; Dr Ritu Garg, Chief Growth and Innovation Officer, Fortis Healthcare and Mr Yash Rawat, Facility Director, FMRI, Gurugram.